Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation
Open Access
- 16 December 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 144 (2), 403-414
- https://doi.org/10.1007/s00432-017-2556-6
Abstract
Metronomic capecitabine (MC) is a well-tolerated systemic treatment showing promising results in one retrospective study, as second-line therapy after sorafenib failure, in patients with hepatocellular carcinoma (HCC).This publication has 36 references indexed in Scilit:
- Metronomic Capecitabine in Patients With Hepatocellular Carcinoma Unresponsive to or Ineligible for Sorafenib Treatment: Report of Two CasesHepatitis Monthly, 2013
- Sorafenib versus capecitabine in the management of advanced hepatocellular carcinomaMedical Oncology, 2013
- Phase II, Open-Label Study of Brivanib as Second-Line Therapy in Patients with Advanced Hepatocellular CarcinomaClinical Cancer Research, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal of Cancer, 2012
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in ItalyJournal of Hepatology, 2011
- Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled TrialAnnals of Surgical Oncology, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Management of hepatocellular carcinomaJournal of Hepatology, 2005
- The anti-angiogenic basis of metronomic chemotherapyNature Reviews Cancer, 2004
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001